OraSure's OraQuick is first rapid HCV test approved
This article was originally published in The Gray Sheet
Executive Summary
Firm gains PMA approval for its OraQuick hepatitis C virus (HCV) rapid antibody test, making it the first rapid HCV test on the U.S. market, the company announces June 25. "Getting faster treatment is an important public health step to control this dangerous disease," CDRH Director Jeffrey Shuren said in a same-day release. The test uses venous whole blood to provide results in about 20 minutes. Last summer, the firm said it would conduct additional clinical studies to satisfy concerns raised by FDA (1"The Gray Sheet" June 29, 2009). Under a previous collaboration deal, Merck will promote the test in the physicians' office market, OraSure notes
You may also be interested in...
OraSure Will Conduct New Clinical Trial For Pending PMA
OraSure Technologies must conduct a new clinical trial to support its OraQuick Hepatitis C (HCV) test PMA application, after an about-face by FDA reviewers, the firm said last week
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.